Basic Facts & Figures
World Headquarters
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
Chairman and CEO
Fred Hassan
Number of employees
51,000
Net sales (2008)
$18.5 billion
Business Operations in
more than 140 countries
Largest-selling products
VYTORIN*, ZETIA*, REMICADE, NASONEX, TEMODAR
R&D investment (2008)
$3.5 billion
Areas of research
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $4.5 billion in 2008.
